Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-04-19 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于公司未弥补亏损达到实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the company's accumulated losses reaching one-third of its paid-in capital. It references an audit by Ernst & Young Hua Ming LLP as of December 31, 2022, and discusses the financial condition and board resolutions related to this situation. The document is relatively short (847 characters) and serves as a formal disclosure of a financial condition and related board decisions, not a full financial report or audit report. It does not contain detailed financial statements or comprehensive analysis but rather a regulatory announcement about the company's financial status and board meeting outcomes. This fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific report types.
2023-04-19 Chinese
北京康乐卫士生物技术股份有限公司募集资金存放与实际使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况鉴证报告" which translates to "Verification Report on the Deposit and Actual Use of Raised Funds" for the year ending December 31, 2022. It contains detailed information about the amounts raised through multiple fundraising rounds, the timing of fund receipt, usage of the funds, changes in fund usage, and compliance with regulatory requirements. The report includes auditor's verification and opinions, referencing specific regulatory guidelines related to the management and use of raised funds by listed companies. The document is about the management and use of capital raised by the company, with auditor verification, but it is not a full annual report or interim financial report. It is a standalone audit-related verification report focused on fundraising and capital usage. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification letter, so it is not RPA or RNS. Hence, the classification is AR with high confidence.
2023-04-19 Chinese
第四届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting date, attendance, and the approval of various reports including the 2022 Supervisory Board Work Report, 2022 Annual Report and its summary, 2022 Financial Final Report, 2023 Financial Budget Report, 2022 Audit Report, and other governance and financial related reports. The document is not the reports themselves but a formal announcement of the resolutions passed in the Supervisory Board meeting. It also states that these reports are disclosed on the Beijing Stock Exchange information platform, indicating this document is a meeting resolution announcement rather than the actual reports. The document length is 3177 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best into the category of Regulatory Filings (RNS) as it is a formal regulatory announcement of meeting resolutions and approvals, not the reports themselves or their detailed contents.
2023-04-19 Chinese
关于公司治理专项自查及规范活动相关情况的报告
Governance Information Classification · 95% confidence The document is a detailed report on the company's governance self-inspection and compliance activities, including information about the board structure, internal controls, shareholder meetings, and compliance with relevant laws and regulations. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy solicitation. The content focuses on governance practices and internal control mechanisms, which aligns with the category of Governance Information (CGR). The document length (5504 characters) and detailed governance content support this classification with high confidence.
2023-04-19 Chinese
独立董事关于第四届董事会第十八次会议审议事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including the use of raised funds, loss coverage, profit distribution, and guarantees. It is a formal announcement related to board meeting decisions and compliance with regulations, but it does not contain financial statements or detailed financial data. The document is relatively short (965 characters) and serves as an official opinion or announcement rather than a full report. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management opinions.
2023-04-19 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the completion of industrial and commercial registration changes and the filing of the company's articles of association, along with obtaining a new business license. It details changes in registered capital, company type, and amendments to the articles of association following a stock issuance and listing on the Beijing Stock Exchange. The document is short (1217 characters) and serves as a formal notification of these corporate changes rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the registration completion. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-04-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.